Expert Interview
Exploring Imetelstat's Role in Treating Transfusion-Dependent Anemia in Lower-Risk MDS: A Deep Dive into Geron's Clinical Advancements
Ticker(s): GERNInstitution: Mount Sinai
- Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, MDS & Leukemia Groups
- Focus on novel therapeutic drug development in MDS, MPN, AML, ALL
- Translational Research on the Impact of the immune microenvironment on disease pathogenesis
Considering the significant achievement of RBC-TI in the IMerge Phase 3 trial, can you discuss how imetelstat influences this clinical outcome, especially in comparison to existing treatments for LR-MDS?
With data showing a median 80-week duration for patients achieving ≥24-week RBC-TI, what are the potential long-term benefits of imetelstat for LR-MDS patients?
How does imetelstat perform across different subgroups of MDS, particularly considering factors like ring sideroblast status and baseline transfusion burden?
Given the reported Grade 3-4 adverse events, such as thrombocytopenia and neutropenia, how can these be effectively managed in clinical settings?
Can you elaborate on the role of imetelstat in achieving hematologic improvement erythroid (HI-E) in MDS patients, as defined by the 2006 IWG criteria?
How does imetelstat's clinical profile compare with other treatments for LR-MDS, especially in terms of efficacy and safety?
Could you provide insights into the patient demographics in the IMerge Phase 3 trial and how they might influence the generalizability of the trial results?
Assuming successful FDA approval following the PDUFA target action date, what are the anticipated next steps for imetelstat, both in clinical practice and further research?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
